W

WEINBLATT ME

Last name: WEINBLATT ME

2015 (v1)

Publication

Metadata-only

Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.

Weinblatt ME Fleischmann R van Vollenhoven RF

Introduction: This 28-week, phase IIIb study assessed safety and maintenance of response to certolizumab pegol (CZP) in a diverse population of rheumatoid arthritis (RA) patients, stratified by prior anti-TNF exposure, concomitant methotrexate (MTX) use and disease duration. The ability to predict achievement of low disease activity (LDA) at...

Uploaded on: April 14, 2023